Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2005-02-01
This is a multicenter, open-label, randomized, parallel group comparison study to verify the
clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of
solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in
patients with perennial allergic rhinitis.
Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active
control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with
perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper
airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by
house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal
congestion, rhinorrhea and/or nasal itching.
Short Term Growth in Children With Atopic Dermatitis
Completed
Children´s Clinic, Randers
Phase 4
2005-02-01
Main objective:to assess short term growth in children with atopic dermatitis during
treatment with tacrolimus 0.1% and mometasone furoate 0.1%. A singl blind randomised cross
over trial including 20 children. The study consists of 5 periods: run in, treatment(1),wash
out, treatment(2) and run out. Each period 14 days where the children will use tacrolimus
ointment tvice daily, mometasone furoate once daily or moisturizer (in run in wash out and
run out)
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
Completed
Integrated Therapeutics Group
Phase 4
2006-05-01
This study will hope to show that by relieving the participant's nasal symptoms of seasonal
allergies using mometasone furoate nasal spray, the participant will obtain a better quality
of night-time sleep, which in turn, causes less daytime sleepiness so that he/she can
function productively during the day.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
